Genzyme General News

Brain drug delivery company to-BBB, has entered into a research collaboration with Genzyme Corporation to evaluate to-BBB's proprietary G-Technology to enhance delivery of biologics for neurodegenerative diseases.

Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the... MEDFORD, N.J.-- --On Wednesday November 18th, Marc Whitten, general manager of Microsoft's Xbox LIVE group will kick off the show with a morning keynote that will explore how today&#8217... CHICAGO-- --Zacks Equity Research highlights ...

Osiris Therapeutics, Inc., today announced that the company has achieved a $15 million milestone payment from NuVasive related to the sale of the Osteocel business.

On 11/3/09, EXACT Sciences reported its 3Q09 results and held a conference call to outline the Company's progress and timeline for the development of a stool DNA based test kit for the early diagnosis and prevention of colorectal cancer .

It may be a time of state budget cuts and stalled private development, but in Framingham both the public and private sectors are moving forward on a major biomanufacturing project.

Former Genzyme Corp. senior executive Mara Aspinall has taken the helm of a new cancer diagnostics business, On-Q-ity Inc.

Former Genzyme Corp. senior executive Mara Aspinall has taken the helm of new cancer diagnostics business On-Q-ity Inc., the Boston Globe reports.

When a company treats rare diseases, with very few patients, revenue can be pretty wonky from quarter to quarter as inventory levels can have a major effect on revenue.

17-19 in Boston, MA. This year's list will offer a Top 10 in each of four therapeutic areas: cardiovascular/metabolic, oncology, neuroscience and inflammatory/autoimmune. Past Windhover top 10 candidates signed a total potential value of $17 billion US in acquisitions and alliances.

The town of Framingham has won $7.7 million from the Massachusetts Life Sciences Center for a wastewater system related to a Genzyme Corp.

The following economic data was released during the session: Headline Indices The Dow Jones Industrial Average declined 92.12 points to 9949.36 points.

Boston Herald General Economics Reporter Jay Fitzgerald has been a journalist and blogger for years.

Yaron Werber -- Citi Salveen Kochnover -- Collins Stewart Mark Schoenebaum -- Deutsche Bank Rachel McMinn a ' Bank of America-Merrill Lynch Eun Yang -- Jefferies & Co.

Genzyme reported lower third-quarter earnings Wednesday that fell below Wall Street expectations, and the company once again slashed profit expectations for the year.

Drug stocks were mildly mixed in morning trading Wednesday as shares of Genzyme Corp.

Genzyme 's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, it's still dealing with the aftermath.

Genzyme Corporation announced that the company has begun enrollment in the first of two global, multi-center, phase 3 trials of Genz-112638, a potential new oral therapy for Gaucher disease type 1. The two multi-national, multi-center trials are being conducted to evaluate the safety and efficacy of the small molecule.

Genzyme Corp., said profit fell 87 percent as a plant closure restricted drug supplies, and the company lowered its full-year earnings forecast Third-quarter net income fell to $16 million, or 6 cents a share, from $119.6 million, or 42 cents, a year earlier, the Cambridge, Massachusetts-based company said today in a statement.

This morning, Genzyme Corp reported third quarter earnings of 19 cents per share, which was well below the Zacks Consensus Estimate of 31 cents and the year ago earnings of 93 cents.

InvestorSoup.com announces an investment report featuring Inovio Biomedical Corp.